Nuclear Medicine and Biology
Volume 33, Issue 1 , Pages 29-35 , January 2006

Acquisition of resistance to antitumor alkylating agent ACNU: a possible target of positron emission tomography monitoring

  • Hideya Kawai

      Affiliations

    • Department of Neurosurgery, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan
    • Research Institute of Brain and Blood Vessels, Akita 010-0874, Japan
    • ,
  • Jun Toyohara

      Affiliations

    • Radiopharmaceutical Chemistry Section, Department of Medical Imaging, National Institute of Radiological Sciences, Chiba 263-8555, Japan
    • Biomedical Imaging Research Center, University of Fukui, Fukui 910-1193, Japan
    • ,
  • Hirotsugu Kado

      Affiliations

    • Research Institute of Brain and Blood Vessels, Akita 010-0874, Japan
    • ,
  • Takao Nakagawa

      Affiliations

    • Department of Neurosurgery, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan
    • ,
  • Shinji Takamatsu

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Fukui 910-1193, Japan
    • ,
  • Takako Furukawa

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Fukui 910-1193, Japan
    • ,
  • Yoshiharu Yonekura

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Fukui 910-1193, Japan
    • ,
  • Toshihiko Kubota

      Affiliations

    • Department of Neurosurgery, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan
    • ,
  • Yasuhisa Fujibayashi

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Fukui 910-1193, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 776 61 8430; fax: +81 776 61 8170.

Received 2 August 2005 ,Revised 2 October 2005 ,Accepted 4 October 2005.

References 

  1. Haioun C, Itti E, Rahmouni A, Meignan M, Reyes F. PET scan in the therapeutic strategy. Hematol J. 2004;5(Suppl 3):S149–S153
  2. Vaidyanathan G, Zalutsky MR. Imaging drug resistance with radiolabeled molecules. Curr Pharm Des. 2004;10(24):2965–2979
  3. Gaa J, Rummeny EJ, Seemann MD. Whole-body imaging with PET/MRI. Eur J Med Res. 2004;9(6):309–312
  4. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [18F]FLT and positron emission tomography. Nat Med. 1998;4(11):1334–1336
  5. Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, et al. Evaluation of 3′-deoxy-3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med. 2004;45(10):1754–1758
  6. van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, de Vries EF, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45(4):695–700
  7. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44(9):1426–1431
  8. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-Deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63(13):3791–3798
  9. Shibui S. Randomized controlled trial on malignant brain tumors — activities of the Japan Clinical Oncology Group-Brain Tumor Study Group. Neurol Med Chir (Tokyo). 2004;44(4):220–221
  10. Saito Y, Hotta T, Mikami T, Kurisu K, Kawamoto K, Kiya K, et al. Establishment of ACNU-resistant rat gliosarcoma cell lines and their characteristics. Neurol Med Chir (Tokyo). 1991;31(13):846–852
  11. Thomale J, Huh NH, Nehls P, Eberle G, Rajewsky MF. Repair of O6–ethylguanine in DNA protects rat 208F cells from tumorigenic conversion by N-ethyl-N-nitrosourea. Proc Natl Acad Sci U S A. 1990;87(24):9883–9887
  12. Mineura K, Fushimi S, Kowada M, Isowa G, Ishizaki K, Ikenaga M. Linkage between O6-methylguanine-DNA methyltransferase (O6-MT) activity and cellular resistance to antitumour nitrosoureas in cultured rat brain tumour cell strains. Acta Neurochir (Wien). 1990;103(1–2):62–66
  13. Karran P, Lindahl T, Griffin B. Adaptive response to alkylating agents involves alteration in situ of O6-methylguanine residues in DNA. Nature. 1979;280(5717):76–77
  14. Kabuto M, Kubota T, Kobayashi H, Nakagawa T, Kitai R. The antitumor effect of MX2, a new morpholino anthracycline, against malignant glioma cell lines and its subcellular distribution. Neurosurgery. 1995;37(3):471–476[discussion 476–7]
  15. Mineura K, Watanabe K, Yanagisawa T, Kowada M. Quantification of O6-methylguanine-DNA methyltransferase mRNA in human brain tumors. Biochim Biophys Acta. 1996;1289(1):105–109
  16. Ayusawa D, Shimizu K, Koyama H, Kaneda S, Takeishi K, Seno T. Cell-cycle-directed regulation of thymidylate synthase messenger RNA in human diploid fibroblasts stimulated to proliferate. J Mol Biol. 1986;190(4):559–567
  17. Takamiya Y, Abe Y, Tanaka Y, Tsugu A, Kazuno M, Oshika Y, et al. Murine P-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts. Br J Cancer. 1997;76(4):445–450
  18. Wang J, Chen Z, Xia X, Lu D, Xue J, Ruan C. Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells. Leuk Res. 2002;26(3):281–288
  19. Engelbergs J, Thomale J, Rajewsky MF. Role of DNA repair in carcinogen-induced ras mutation. Mutat Res. 2000;450(1–2):139–153
  20. Anda T, Shabani HK, Tsunoda K, Tokunaga Y, Kaminogo M, Shibata S, et al. Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res. 2003;25(3):241–248
  21. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol. 2001;2001(Suppl):96S–103S
  22. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36(4):808–818
  23. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43(9):1210–1217
  24. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validation for positron emission tomography. Nucl Med Biol. 2004;31:829–837
  25. Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G, et al. Neumaier, 3-deoxy-3-[18F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002;62(12):3331–3334
  26. Toyohara J, Waki A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H] thymidine and [3H] arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29(3):281–287
  27. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, et al. Early changes in [18F] FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29(11):1462–1469

PII: S0969-8051(05)00262-3

doi: 10.1016/j.nucmedbio.2005.10.002

Nuclear Medicine and Biology
Volume 33, Issue 1 , Pages 29-35 , January 2006

Article Tools

* Image Usage & Resolution